Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 152 No. 2324 (2022)

Low total gamma globulin level discovery at diffuse large B-cell lymphoma diagnosis predicts high risk of infection-related death: data from a monocentric retrospective study

  • Alexandre Nguyen
  • Nicolas Martin-Silva
  • Hubert de Boysson
  • Samuel Deshayes
  • Anne-Claire Gac
  • Emilie Reboursière
  • Gandhi Damaj
  • Achille Aouba
DOI
https://doi.org/10.4414/SMW.2022.w30143
Cite this as:
Swiss Med Wkly. 2022;152:w30143
Published
06.06.2022

Summary

OBJECTIVE: Diffuse large B-cell lymphoma can complicate the course of B-cell primary immunodeficiencies or induce lowering of total gamma globulin levels, whose clinical status as an effective secondary immunodeficiency remains unspecified. This study aimed to assess the frequency, and clinical and prognostic relevance of the low total gamma-globulin levels discovered at diagnosis of diffuse large B-cell lymphoma.

RESULTS: In a 2-year monocentric retrospective study, 96 patients diagnosed with diffuse large B-cell lymphoma who had a serum electrophoresis were included. Patients were divided into those with lower (L-TGL and higher (H-TGL) total gamma-globulin levels (total gamma-globulin levels ≤5.5 g/l and >5.5 g/l) and compared for outcomes, including fatal infectious events.  Twelve (12.5%; 8 males; age median  68 years, range 55—82 years) exhibited L-TGL. There was no difference between the both groups regarding demographics, Ann Arbor lymphoma stage, inflammatory parameters or chemotherapy regimen. However, overall death rates (10/12, 83.3% versus 22/96, 26.2%; p = 0.03) and infection-related death rates (10/12, 83% versus 6/96, 6.2%; p <0.001) were significantly higher in the L-TGL group.

CONCLUSION: We demonstrate for the first time the strong negative impact of L-TGL on overall and infection-related mortality in diffuse large B-cell lymphoma. Prospective studies should distinguish immunodeficiencies secondary to the lymphoma from pre-existing humoral primary immunodeficiencies, using biomolecular testing and post-treatment total gamma-globulin level monitoring, to determine the best management strategy for infectious risk during diffuse large B-cell lymphoma treatment in the context of L-TGL.

References

  1. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol. 1987 Jul;7(4):294–9. https://doi.org/10.1007/BF00915550
  2. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011 Jun;127(6):1329–41.e2. https://doi.org/10.1016/j.jaci.2011.02.047
  3. Baldovino S, Montin D, Martino S, Sciascia S, Menegatti E, Roccatello D. Common variable immunodeficiency: crossroads between infections, inflammation and autoimmunity. Autoimmun Rev. 2013 Jun;12(8):796–801. https://doi.org/10.1016/j.autrev.2012.11.003
  4. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood. 2010 Aug;116(8):1228–34. https://doi.org/10.1182/blood-2010-03-272351
  5. Shapiro RS. Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am J Hematol. 2011 Jan;86(1):48–55. https://doi.org/10.1002/ajh.21903
  6. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008 Sep;22(5):261–81. https://doi.org/10.1016/j.blre.2008.03.009
  7. Mellemkjaer L, Hammarström L, Andersen V, Yuen J, Heilmann C, Barington T, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002 Dec;130(3):495–500. https://doi.org/10.1046/j.1365-2249.2002.02004.x
  8. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al.; DEFI Study Group. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008 May;46(10):1547–54. https://doi.org/10.1086/587669
  9. Cunningham-Rundles C. The many faces of common variable immunodeficiency. Hematology (Am Soc Hematol Educ Program). 2012;2012(1):301–5. https://doi.org/10.1182/asheducation.V2012.1.301.3798316
  10. CEREDIH: The French PID study group. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010 May;135(2):264–72. https://doi.org/10.1016/j.clim.2010.02.021
  11. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015 Nov;35(8):696–726. https://doi.org/10.1007/s10875-015-0201-1
  12. Chan HY, Yang YH, Yu HH, Chien YH, Chiang LL, Chiang BL. Clinical characteristics and outcomes of primary antibody deficiency: a 20-year follow-up study. J Formos Med Assoc. 2014 Jun;113(6):340–8. https://doi.org/10.1016/j.jfma.2012.07.005
  13. Dabaja BS, Advani R, Hodgson DC, Dhakal S, Flowers CR, Ha CS, et al. ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. Am J Clin Oncol. 2015 Dec;38(6):610–20. https://doi.org/10.1097/COC.0000000000000215
  14. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, et al. NCCN Guidelines Insights: Non-Hodgkin’s Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016 Sep;14(9):1067–79. https://doi.org/10.6004/jnccn.2016.0117
  15. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al.; ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v116–25. https://doi.org/10.1093/annonc/mdv304
  16. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009 May;50(5):764–72. https://doi.org/10.1080/10428190902856824
  17. Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017 Jun;188(3):333–41. https://doi.org/10.1111/cei.12915
  18. Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management [Internet]. Front Immunol. 2019 Feb;10:33. [cited 2020 Aug 24] Available from: https://www.frontiersin.org/article/10.3389/fimmu.2019.00033/full https://doi.org/10.3389/fimmu.2019.00033
  19. Benbrahim O, Viallard JF, Choquet S, Royer B, Bauduer F, Decaux O, et al. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. Eur J Haematol. 2018 Jul;101(1):48–56. https://doi.org/10.1111/ejh.13078
  20. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al.; ESID Registry Working Party and collaborators. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763–70. https://doi.org/10.1016/j.jaip.2019.02.004
  21. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013 Nov;174(2):203–11. https://doi.org/10.1111/cei.12178
  22. Ameratunga R, Woon ST. Perspective: Evolving Concepts in the Diagnosis and Understanding of Common Variable Immunodeficiency Disorders (CVID). Clin Rev Allergy Immunol. 2020 Aug;59(1):109–21. https://doi.org/10.1007/s12016-019-08765-6
  23. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016 Oct;101(10):1244–50. https://doi.org/10.3324/haematol.2016.148809
  24. Desandes E, Lacour B, Clavel J. le Réseau français des registres de cancers [Cancer in adolescents and young adults in France: Epidemiology and pathways of care]. Bull Cancer (Paris). 2016 Dec;103(12):957–65. https://doi.org/10.1016/j.bulcan.2016.09.020
  25. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018 Sep;4(9):1221–7. https://doi.org/10.1001/jamaoncol.2018.2128
  26. Wang Y, Achenbach SJ, Rabe KG, Shanafelt TD, Call TG, Ding W, et al. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer J. 2021 Aug;11(8):140. https://doi.org/10.1038/s41408-021-00532-1
  27. Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017 Aug;178(3):394–402. https://doi.org/10.1111/bjh.14785
  28. Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018 Jan;11(1):57–70. https://doi.org/10.1080/17474086.2018.1407645
  29. Mahlaoui N, Picard C, Bach P, Costes L, Courteille V, Ranohavimparany A, et al.; CEREDIH French PID study group. Genetic diagnosis of primary immunodeficiencies: A survey of the French national registry. J Allergy Clin Immunol. 2019 Apr;143(4):1646–1649.e10. https://doi.org/10.1016/j.jaci.2018.12.994

Most read articles by the same author(s)